*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Summary Sentence: "Glycoproteomic Discovery of Cancer Biomarkers" - Karen L. Abbott, PhD - University of Georgia
Full Summary: Georgia Tech has been a leader in the development of collaborative approaches to both cancer diagnostics and therapeutics. The mission of the Integrated Cancer Research Center (ICRC) is to facilitate integration of the diversity of technological, computational, scientific and medical expertise at Georgia Tech and partner institutions in a coordinated effort to develop improved cancer diagnostics and therapeutics.
Karen L. Abbott, PhD - University of Georgia"Glycoproteomic Discovery of Cancer Biomarkers"
Karen L. Abbott, PhD
Assistant Research Professor
Complex Carbohydrate Research Center
University of Georgia
Glycosylation is a posttranslational modification that changes early in cancer cells favoring the growth and progression of the tumor. We have developed glycoproteomic techniques that enable the identification of glycoproteins that carry tumor-specific glycans using lectin capture followed by nano-ESI-RPLC-MS/MS analysis. The application of these methods for breast and ovarian cancer has led to the identification of new biomarkers that are common to diverse molecular and histological subtypes of breast and ovarian cancer. These results indicate that the detection of tumor-specfic glycan changes on specific glycoproteins may be useful for the development of population wide screening for breast and ovarian cancers. Furthermore, these studies offer new insights into functional roles of tumor-specific glycan modifications that may be exploited for the development of future therapeutics.
